Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Mylan | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Mylan

North America sales down 6% due to changes in the competitive environment and the impact of Morgantown plant remediation

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Mylan
1Q Revenues: $2.5 billion (-7%)
1Q Loss: $25 million (earnings were $87.1 million)
Comments: North America sales were $922.9 million, down 6% primarily driven by changes in the competitive environment and the impact of the Morgantown plant remediation activities, partially offset by new product sales, including Wixela Inhuband Fulphila (biosimilar to Neulasta), and increased market share on Glatiramer Acetate Injection. Rest of World segment sales were $642.4 million, up 3%. Europe segment sales were $895.3 million, down 14%. Mylan’s sales were unfavorably impacted by foreign currency translation, primarily reflecting changes in the U.S. Dollar as compared to the currencies of Mylan’s subsidiaries in India, Australia, and the EU.

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters